Introduction
Cryptosporidium sp. are waterborne gastrointestinal protozoa that are ubiquitous in industrialized and developing countries. In immunocompromised patients, Cryptosporidium can cause a severe and chronic diarrheal disease, whereas in immunocompetent patients, the disease follows a milder course and infection is often asymptomatic.2–5 In developing countries where access to clean water sources is limited, Cryptosporidium is one of the commonest causes of parasitic diarrheal disease in children less than five years of age.
These children often experience repeated infections with this parasite,leading to significant growth and developmental delays,9–11 even in children with asymptomatic infection. Cryptosporidiosis is also associated with malnutrition, although cause and effect remain unclear. Currently, treatment and prevention options are severely limited: there is no vaccine, and nitazoxanide, the only drug approved for treatment of cryptosporidiosis,18 is ineffective in immunocompromised patients.19
To develop better prevention and treatment strategies, it is important to characterize the immune responses to the parasite. Although the CD4+ immune response is essential for control of infection,20 the serum antibody response to immunodominant antigens is correlated with protection from symptoms.21 The humoral immune response has not been shown to directly participate in clearance of the parasite, and may well simply reflect development of protective cellular responses. However, several studies have found that patients with acquired immunodeficiency syndrome living in areas where cryptosporidiosis is endemic often have asymptomatic cryptosporidiosis even when severely immunosupressed.22,23 This observation suggests that in the absence of a robust CD4+ response, other immune responses such as antibodies or cytokines, may make a more significant contribution to protection from symptomatic infection.
There are two Cryptosporidium species (C. hominis and C. parvum) that cause most human infections.
Some antigens, such as the immunodominant Cp23 and gp15, are relatively conserved between the two species.25,26 A previous study from our group in this cohort of children using recombinant gp15 from both species as antigens in an enzyme-linked immunosorbent assay (ELISA) showed that both antigens induced serum antibody responses, and that there was cross-reactivity between gp15 from C. hominis and C. parvum.27 Similarly, the immunodominant p23 antigen induced significant serum antibody responses in case children compared with controls in this study (Borad AJ and others, unpublished data).
However, it is now recognized that Cryptosporidium also expresses antigens that are polymorphic between species and among isolates, most notably gp40,24,28,29 and the more recently described Muc4 and Muc5. These antigens have also been implicated in the processes of parasite attachment and invasion, suggesting that an immune response directed against these antigens might be critically important for protection. Gp40 is highly polymorphic among C. hominis and C. parvum isolates; to date, 20 alleles of this gene have been identified.
A previous study from our group that investigated antibody responses to gp40 in children in southern India with cryptosporidiosis found that serum IgG responses to this antigen, although cross-reactive, are in part subtype specific.
Rabbit anti-LukA pAb |
|||
| 0316-001 | IBT Bioservices | 100ug | 375 EUR |
Recombinant S. aureus LukA-LukB (tag free) |
|||
| 0510-001 | IBT Bioservices | 100ug | 468.75 EUR |
Rabbit anti-Staphylococcus aureus lukF Polyclonal Antibody |
|||
| MBS7155154-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Anti-Staphylococcus aureus LukAB/LukGH Antibody |
|||
| MBS1569300-01mg | MyBiosource | 0.1mg | 405 EUR |
Anti-Staphylococcus aureus LukAB/LukGH Antibody |
|||
| MBS1569300-5x01mg | MyBiosource | 5x0.1mg | 1520 EUR |
human anti-Staphylococcus aureus LukAB IgG |
|||
| E4A11A47-LAB-G | EnoGene | 50ug | 275 EUR |
human anti-Staphylococcus aureus LukAB IgM |
|||
| E4A11A47-LAB-M | EnoGene | 50ug | 275 EUR |
Human anti-Staphylococcus aureus LukAB IgG |
|||
| A11A47-LAB-G | BioNC | 1 Each | Ask for price |
Human anti-Staphylococcus aureus LukAB IgM |
|||
| A11A47-LAB-M | BioNC | 1 Each | Ask for price |
Human Anti-S. aureus LukAB Monoclonal antibody, clone 870 |
|||
| DMAB-CS23050 | Creative Diagnostics | 100 μg | 980 EUR |
Rabbit Anti BSA |
|||
| E61I026 | EnoGene | 0.1mg | 225 EUR |
Rabbit anti BNP |
|||
| MBS315608-01mL | MyBiosource | 0.1mL | 640 EUR |
Rabbit anti BNP |
|||
| MBS315608-5x01mL | MyBiosource | 5x0.1mL | 2695 EUR |
Rabbit anti BNP |
|||
| MBS315609-01mL | MyBiosource | 0.1mL | 1590 EUR |
Rabbit anti BNP |
|||
| MBS315609-5x01mL | MyBiosource | 5x0.1mL | 6985 EUR |
Rabbit anti PSA |
|||
| MBS315621-1mL | MyBiosource | 1mL | 325 EUR |
Rabbit anti PSA |
|||
| MBS315621-5x1mL | MyBiosource | 5x1mL | 1280 EUR |
Rabbit anti tPA |
|||
| MBS315815-02mg | MyBiosource | 0.2mg | 610 EUR |
Rabbit anti tPA |
|||
| MBS315815-5x02mg | MyBiosource | 5x0.2mg | 2570 EUR |
Although there is only 58% identity between the C. hominis and C. parvum Muc4 alleles
there is little polymorphism at the Muc4 locus among C. hominis isolates, except for those isolates identified as human-adapted or anthroponotic C. parvum.However, the nature and specificity of the immune response to Muc4 remain uncharacterized. To initiate studies on the immune response to Muc4 and the level of cross reactivity to the two protein isoforms, we expressed the C. hominis and C. parvum Muc4 proteins in Escherichia coli and examined antibody responses to both proteins in a cohort of children in Bangladesh infected with C. hominis.
